Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 688

1.

Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent Prognosis.

Kriegsmann K, Klee JS, Hensel M, Buss EC, Kriegsmann M, Cremer M, Ho AD, Egerer G, Wuchter P, Witzens-Harig M.

Clin Lymphoma Myeloma Leuk. 2019 May 30. pii: S2152-2650(18)31718-X. doi: 10.1016/j.clml.2019.05.019. [Epub ahead of print]

PMID:
31377211
2.

Evolution of Peripheral Blood Stem Cell Transplantation.

Ho AD.

Methods Mol Biol. 2019;2017:1-10. doi: 10.1007/978-1-4939-9574-5_1.

PMID:
31197764
3.

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.

Schubert ML, Schmitt A, Sellner L, Neuber B, Kunz J, Wuchter P, Kunz A, Gern U, Michels B, Hofmann S, Hückelhoven-Krauss A, Kulozik A, Ho AD, Müller-Tidow C, Dreger P, Schmitt M.

BMJ Open. 2019 May 19;9(5):e026644. doi: 10.1136/bmjopen-2018-026644.

4.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study.

Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ.

Haematologica. 2019 Apr 19. pii: haematol.2018.208678. doi: 10.3324/haematol.2018.208678. [Epub ahead of print]

5.

Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis.

Hoffmann A, Dietrich S, Hain S, Rieger M, Hegenbart U, Sellner L, Ho AD, Müller-Tidow C, Dreger P.

Haematologica. 2019 Jul;104(7):e304-e306. doi: 10.3324/haematol.2018.209486. Epub 2019 Jan 10. No abstract available.

6.

Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects.

Wang L, Ni M, Hückelhoven-Krauss A, Sellner L, Hoffmann JM, Neuber B, Luft T, Hegenbart U, Schönland S, Kleist C, Sill M, Chen BA, Wuchter P, Eckstein V, Krüger W, Hilgendorf I, Yerushalmi R, Nagler A, Müller-Tidow C, Ho AD, Dreger P, Schmitt M, Schmitt A.

Front Immunol. 2018 Oct 8;9:2207. doi: 10.3389/fimmu.2018.02207. eCollection 2018.

7.

Cell-specific proteome analyses of human bone marrow reveal molecular features of age-dependent functional decline.

Hennrich ML, Romanov N, Horn P, Jaeger S, Eckstein V, Steeples V, Ye F, Ding X, Poisa-Beiro L, Lai MC, Lang B, Boultwood J, Luft T, Zaugg JB, Pellagatti A, Bork P, Aloy P, Gavin AC, Ho AD.

Nat Commun. 2018 Oct 1;9(1):4004. doi: 10.1038/s41467-018-06353-4.

8.

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.

Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, Hundemer M, Jauch A, Hegenbart U, Raab MS, Ho AD, Schönland S, Hose D.

Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018.

9.

Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.

Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A.

Nature. 2018 Aug;560(7718):E28. doi: 10.1038/s41586-018-0403-9.

PMID:
30069041
10.

Selective contrast-enhanced computed tomography is appropriate in diffuse large B-cell lymphoma therapy response assessment.

Kriegsmann K, Wack M, Kriegsmann M, Cremer M, Bruckner T, Ho AD, Wuchter P, Witzens-Harig M.

Eur J Haematol. 2018 Jul 24. doi: 10.1111/ejh.13150. [Epub ahead of print]

PMID:
30047174
11.

Simple Physical Model Unravels Influences of Chemokine on Shape Deformation and Migration of Human Hematopoietic Stem Cells.

Ohta T, Monzel C, Becker AS, Ho AD, Tanaka M.

Sci Rep. 2018 Jul 13;8(1):10630. doi: 10.1038/s41598-018-28750-x.

12.

A prospective study on serum Cytokeratin (CK)-18 and CK18 fragments as biomarkers of acute hepato-intestinal GVHD.

Sauer S, Hüsing J, Hajda J, Neumann F, Radujkovic A, Ho AD, Dreger P, Luft T.

Leukemia. 2018 Dec;32(12):2685-2692. doi: 10.1038/s41375-018-0183-0. Epub 2018 Jun 27.

PMID:
29950693
13.

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, Sanchi A, Radujkovic A, Horn P, Dolatshad H, Roy S, Broxholme J, Lockstone H, Taylor S, Giagounidis A, Vyas P, Schuh A, Hamblin A, Papaemmanuil E, Killick S, Malcovati L, Hennrich ML, Gavin AC, Ho AD, Luft T, Hellström-Lindberg E, Cazzola M, Smith CWJ, Smith S, Boultwood J.

Blood. 2018 Sep 20;132(12):1225-1240. doi: 10.1182/blood-2018-04-843771. Epub 2018 Jun 21.

14.

Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy.

Gdynia G, Robak T, Kopitz J, Heller A, Grekova S, Duglova K, Laukemper G, Heinzel-Gutenbrunner M, Gutenbrunner C, Roth W, Ho AD, Schirmacher P, Schmitt M, Dreger P, Sellner L.

EBioMedicine. 2018 Jun;32:125-133. doi: 10.1016/j.ebiom.2018.05.030. Epub 2018 Jun 5.

15.

CD7 is expressed on a subset of normal CD34-positive myeloid precursors.

Kriegsmann K, Löffler H, Eckstein V, Schulz R, Kräker S, Braun U, Luft T, Hegenbart U, Schönland S, Dreger P, Krämer A, Ho AD, Müller-Tidow C, Hundemer M.

Eur J Haematol. 2018 Sep;101(3):318-325. doi: 10.1111/ejh.13100. Epub 2018 Jul 4.

PMID:
29797671
16.

Author Correction: Dynamic cellular phenotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents.

Monzel C, Becker AS, Saffrich R, Wuchter P, Eckstein V, Ho AD, Tanaka M.

Sci Rep. 2018 Apr 30;8(1):6996. doi: 10.1038/s41598-018-25253-7.

17.

Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

Baertsch MA, Kriegsmann K, Pavel P, Bruckner T, Hundemer M, Kriegsmann M, Ho AD, Goldschmidt H, Wuchter P.

Transfus Med Hemother. 2018 Jan;45(1):24-31. doi: 10.1159/000478911. Epub 2017 Oct 4.

18.

Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.

Kriegsmann K, Dittrich T, Neuber B, Awwad MHS, Hegenbart U, Goldschmidt H, Hillengass J, Hose D, Seckinger A, Müller-Tidow C, Ho AD, Schönland S, Hundemer M.

Cytometry B Clin Cytom. 2018 Sep;94(5):611-620. doi: 10.1002/cyto.b.21636. Epub 2018 Apr 20.

19.

Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma.

Kriegsmann K, Rieger M, Schwarzbich MA, Sitter S, Kriegsmann M, Bruckner T, Hensel M, Ho AD, Witzens-Harig M, Wuchter P.

Eur J Haematol. 2018 Jul;101(1):12-20. doi: 10.1111/ejh.13064. Epub 2018 May 17.

PMID:
29575332
20.

The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.

Rohlfing S, Dietrich S, Witzens-Harig M, Hegenbart U, Schönland S, Luft T, Ho AD, Dreger P.

Ann Hematol. 2018 Jul;97(7):1241-1250. doi: 10.1007/s00277-018-3288-7. Epub 2018 Mar 16.

PMID:
29549411
21.

Improving Measurement Efficiency of the Inner EAR Scale with Item Response Theory.

Jessen A, Ho AD, Corrales CE, Yueh B, Shin JJ.

Otolaryngol Head Neck Surg. 2018 Jun;158(6):1093-1100. doi: 10.1177/0194599818760528. Epub 2018 Mar 7.

PMID:
29512425
22.

Mathematical modeling of the impact of cytokine response of acute myeloid leukemia cells on patient prognosis.

Stiehl T, Ho AD, Marciniak-Czochra A.

Sci Rep. 2018 Feb 12;8(1):2809. doi: 10.1038/s41598-018-21115-4.

23.

Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents.

Monzel C, Becker AS, Saffrich R, Wuchter P, Eckstein V, Ho AD, Tanaka M.

Sci Rep. 2018 Jan 30;8(1):1841. doi: 10.1038/s41598-018-19557-x. Erratum in: Sci Rep. 2018 Apr 30;8(1):6996.

24.

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.

Hoffmann JM, Schubert ML, Wang L, Hückelhoven A, Sellner L, Stock S, Schmitt A, Kleist C, Gern U, Loskog A, Wuchter P, Hofmann S, Ho AD, Müller-Tidow C, Dreger P, Schmitt M.

Front Immunol. 2018 Jan 10;8:1956. doi: 10.3389/fimmu.2017.01956. eCollection 2017.

25.

The molecular signature of AML with increased ALDH activity suggests a stem cell origin.

Blume R, Rempel E, Manta L, Saeed BR, Wang W, Raffel S, Ermakova O, Eckstein V, Benes V, Trumpp A, Ho AD, Lutz C.

Leuk Lymphoma. 2018 Sep;59(9):2201-2210. doi: 10.1080/10428194.2017.1422862. Epub 2018 Jan 16.

PMID:
29334844
26.

HCV load as a possible prognostic factor in patients with HCV-related DLBCL.

Zhou X, Lisenko K, Lehners N, Brandt J, Cremer M, Kriegsmann M, Ho AD, Witzens-Harig M.

Ann Hematol. 2018 Feb;97(2):351-354. doi: 10.1007/s00277-017-3124-5. Epub 2017 Dec 16. No abstract available.

PMID:
29247401
27.

Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells.

Neuber B, Dai J, Waraich WA, Awwad MHS, Engelhardt M, Schmitt M, Medenhoff S, Witzens-Harig M, Ho AD, Goldschmidt H, Hundemer M.

Oncotarget. 2017 Oct 5;8(58):98200-98214. doi: 10.18632/oncotarget.21516. eCollection 2017 Nov 17.

28.

Drug-perturbation-based stratification of blood cancer.

Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Dürig J, Ringshausen I, Zapatka M, Huber W, Zenz T.

J Clin Invest. 2018 Jan 2;128(1):427-445. doi: 10.1172/JCI93801. Epub 2017 Dec 11.

29.

Cisplatin radiosensitizes radioresistant human mesenchymal stem cells.

Rühle A, Perez RL, Glowa C, Weber KJ, Ho AD, Debus J, Saffrich R, Huber PE, Nicolay NH.

Oncotarget. 2017 Sep 23;8(50):87809-87820. doi: 10.18632/oncotarget.21214. eCollection 2017 Oct 20.

30.

BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.

Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A.

Nature. 2017 Nov 16;551(7680):384-388. doi: 10.1038/nature24294. Epub 2017 Nov 8. Erratum in: Nature. 2018 Aug;560(7718):E28.

PMID:
29144447
31.

Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.

Kayser S, Feszler M, Krzykalla J, Schick M, Kramer M, Benner A, Thol F, Platzbecker U, Müller-Tidow C, Ho AD, Ehninger G, Heuser M, Schlenk RF, Thiede C, Röllig C, Krämer A.

Eur J Haematol. 2017 Dec;99(6):544-552. doi: 10.1111/ejh.12972. Epub 2017 Oct 13.

PMID:
28940816
32.

Mesenchymal stromal cells contribute to quiescence of therapy-resistant leukemic cells in acute myeloid leukemia.

Wang W, Bochtler T, Wuchter P, Manta L, He H, Eckstein V, Ho AD, Lutz C.

Eur J Haematol. 2017 Nov;99(5):392-398. doi: 10.1111/ejh.12934. Epub 2017 Sep 13.

PMID:
28800175
33.

Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients.

Lisenko K, Wuchter P, Hansberg M, Mangatter A, Benner A, Ho AD, Goldschmidt H, Hegenbart U, Schönland S.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1870-1878. doi: 10.1016/j.bbmt.2017.07.015. Epub 2017 Jul 25.

34.

The influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkin's lymphomas.

Zhou X, Lisenko K, Lehners N, Egerer G, Ho AD, Witzens-Harig M.

Ann Hematol. 2017 Sep;96(9):1501-1507. doi: 10.1007/s00277-017-3058-y. Epub 2017 Jul 1.

PMID:
28669008
35.

Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.

Lisenko K, Baertsch MA, Meiser R, Pavel P, Bruckner T, Kriegsmann M, Schmitt A, Witzens-Harig M, Ho AD, Hillengass J, Wuchter P.

Transfusion. 2017 Oct;57(10):2359-2365. doi: 10.1111/trf.14211. Epub 2017 Jun 26.

PMID:
28653421
36.

Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD.

Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, Ho AD, Zeier M, Dreger P, Luft T.

Bone Marrow Transplant. 2017 Oct;52(10):1399-1405. doi: 10.1038/bmt.2017.119. Epub 2017 Jun 26.

PMID:
28650448
37.

In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study.

Cremer M, Schwarzbich MA, Schöning T, Lisenko K, Ho AD, Witzens-Harig M.

Ann Hematol. 2017 Sep;96(9):1573-1575. doi: 10.1007/s00277-017-3044-4. Epub 2017 Jun 16. No abstract available.

PMID:
28623395
38.

Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia.

Wang W, Stiehl T, Raffel S, Hoang VT, Hoffmann I, Poisa-Beiro L, Saeed BR, Blume R, Manta L, Eckstein V, Bochtler T, Wuchter P, Essers M, Jauch A, Trumpp A, Marciniak-Czochra A, Ho AD, Lutz C.

Haematologica. 2017 Sep;102(9):1567-1577. doi: 10.3324/haematol.2016.163584. Epub 2017 May 26.

39.

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.

Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, Ho AD, Hegenbart U, Schönland SO.

Blood. 2017 Aug 3;130(5):632-642. doi: 10.1182/blood-2017-02-767475. Epub 2017 May 26.

PMID:
28550043
40.

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.

Lisenko K, Dingeldein G, Cremer M, Kriegsmann M, Ho AD, Rieger M, Witzens-Harig M.

BMC Cancer. 2017 May 22;17(1):359. doi: 10.1186/s12885-017-3332-3.

41.

Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses.

Schmitt M, Schmitt A, Wiesneth M, Hückelhoven A, Wu Z, Kuball J, Wang L, Schauwecker P, Hofmann S, Götz M, Michels B, Maccari B, Wuchter P, Eckstein V, Mertens T, Schnitzler P, Döhner H, Ho AD, Bunjes DW, Dreger P, Schrezenmeier H, Greiner J.

Theranostics. 2017 Apr 10;7(6):1705-1718. doi: 10.7150/thno.18301. eCollection 2017.

42.

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.

Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO.

Haematologica. 2017 Aug;102(8):1424-1431. doi: 10.3324/haematol.2016.163246. Epub 2017 May 18.

43.

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.

Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehners N, Penzel R, Weichert W, Ho AD, Schirmacher P, Goldschmidt H, Andrulis M, Raab MS.

Oncogenesis. 2017 May 15;6(5):e337. doi: 10.1038/oncsis.2017.36.

44.

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.

Milani P, Schönland S, Palladini G, Kimmich C, Basset M, Russo F, Foli A, Perlini S, Bochtler T, Ho AD, Merlini G, Hegenbart U.

Amyloid. 2017 Mar;24(sup1):56-57. doi: 10.1080/13506129.2017.1292240. No abstract available.

PMID:
28434298
45.

Amyloid in bone marrow smears in systemic light-chain amyloidosis.

Kimmich C, Schönland S, Kräker S, Andrulis M, Ho AD, Mayer G, Dittrich T, Hundemer M, Hegenbart U.

Amyloid. 2017 Mar;24(1):52-59. doi: 10.1080/13506129.2017.1314959. Epub 2017 Apr 23.

PMID:
28434267
46.

GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.

Sellner L, Brüggemann M, Schlitt M, Knecht H, Herrmann D, Reigl T, Krejci A, Bystry V, Darzentas N, Rieger M, Dietrich S, Luft T, Ho AD, Kneba M, Dreger P.

Bone Marrow Transplant. 2017 Apr;52(4):656. doi: 10.1038/bmt.2017.12. No abstract available.

PMID:
28377595
47.

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.

Baertsch MA, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K, Noppeney R, Martin H, Lindemann HW, Haenel M, Nogai A, Scheid C, Salwender H, Fenk R, Graeven U, Reimer P, Schmidt-Hieber M, Goerner M, Schmidt-Wolf IGH, Klein S, Ho AD, Goldschmidt H, Wuchter P.

Eur J Haematol. 2017 Jul;99(1):42-50. doi: 10.1111/ejh.12888. Epub 2017 May 24.

PMID:
28370401
48.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

49.

Human haematopoietic stem cell lineage commitment is a continuous process.

Velten L, Haas SF, Raffel S, Blaszkiewicz S, Islam S, Hennig BP, Hirche C, Lutz C, Buss EC, Nowak D, Boch T, Hofmann WK, Ho AD, Huber W, Trumpp A, Essers MA, Steinmetz LM.

Nat Cell Biol. 2017 Apr;19(4):271-281. doi: 10.1038/ncb3493. Epub 2017 Mar 20.

50.

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD.

Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2.

Supplemental Content

Loading ...
Support Center